| |
IMRT (non-IGRT) (No. = 79)
|
HT (IGRT) (No. = 73)
|
P value
|
|---|
|
Variable
| |
No. of patients (%)
| |
|---|
|
Age (years)
| | | |
|
Median
|
48
|
52
|
0.398
|
|
Range
|
29–78
|
24–78
|
|
Gender
| | | |
|
Male
|
78 (98.7 %)
|
70 (95.9 %)
|
0.274
|
|
Female
|
1 (1.3 %)
|
3 (4.1 %)
|
|
Subsite
| | | |
|
Oral tongue
|
25 (31.6 %)
|
35 (47.9 %)
|
0.348
|
|
Buccal mucosa
|
34 (43.0 %)
|
25 (34.2 %)
|
|
Alveolar ridge
|
8 (10.1 %)
|
7 (9.6 %)
|
|
Retromolar trigone
|
5 (6.3 %)
|
3 (4.1 %)
|
|
Floor of the mouth
|
2 (2.5 %)
|
2 (2.7 %)
|
|
Hard palate
|
2 (2.5 %)
|
1 (1.4 %)
|
|
Lip
|
3 (3.8 %)
|
0
|
|
Resection-margin status
| | | |
|
Close or positive
|
39 (49.4 %)
|
42 (57.5 %)
|
0.313
|
|
Negative
|
40 (50.6 %)
|
31 (42.5 %)
|
|
Extracapsular spread
| | | |
|
Positive
|
13 (16.5 %)
|
19 (26.0 %)
|
0.148
|
|
Negative
|
66 (83.5 %)
|
54 (74.0 %)
|
|
Perineural involvement
| | | |
|
Positive
|
49 (62.0 %)
|
60 (82.2 %)
|
0.006
|
|
Negative
|
30 (38.0 %)
|
13 (17.8 %)
|
|
Lymphovascular space involvement
| | | |
|
Positive
|
31 (39.2 %)
|
46 (63.0 %)
|
0.003
|
|
Negative
|
48 (60.8 %)
|
27 (37.0 %)
|
|
Pathology stage:
| | | |
|
Tumor stage
| | | |
|
Stage I
|
6 (7.6 %)
|
8 (11.0 %)
|
0.532
|
|
Stage II
|
12 (15.2 %)
|
12 (16.4 %)
|
|
Stage III
|
18 (22.8 %)
|
15 (20.5 %)
|
|
Stage IVA
|
43 (54.4 %)
|
38 (52.1 %)
|
|
Primary tumor stage
| | | |
|
T1
|
14 (17.7 %)
|
13 (17.8 %)
|
0.768
|
|
T2
|
22 (27.8 %)
|
25 (34.2 %)
|
|
T3
|
18 (22.8 %)
|
11 (15.1 %)
|
|
T4a
|
25 (31.6 %)
|
24 (32.9 %)
|
|
Regional lymph node stage
| | | |
|
N0
|
39 (49.4 %)
|
38 (52.1 %)
|
0.302
|
|
N1
|
15 (19.0 %)
|
7 (9.6 %)
|
|
N2a
|
8 (10.1 %)
|
6 (8.2 %)
|
|
N2b
|
14 (17.7 %)
|
20 (27.4 %)
|
|
N2c
|
3 (3.8 %)
|
1 (1.4 %)
|
|
N3
|
0
|
1 (1.4 %)
|
|
Adjuvant concurrent chemotherapy
| | | |
|
Yes
|
67 (84.8 %)
|
65 (89.0 %)
|
0.442
|
|
No
|
12 (15.2 %)
|
8 (11.0 %)
| |
|
RT dose
| | | |
|
Median (range)
|
66 Gy (59.4–72 Gy)
|
66 Gy (60–70.2 Gy)
|
0.304
|
|
POTT
| | | |
|
≤13 weeks
|
46 (58.2 %)
|
61 (83.6 %)
|
0.001
|
|
>13 weeks
|
33 (41.8 %)
|
12 (16.4 %)
|
|
OTTRT
| | | |
|
≤8 weeks
|
54 (68.4 %)
|
65 (89.0 %)
|
0.002
|
|
>8 weeks
|
25 (31.6 %)
|
8 (11.0 %)
|
- Abbreviations: ECOG Performance Status Eastern Cooperative Oncology Group Performance Status, HT helical tomotherapy, IGRT image-guided radiotherapy, IMRT intensity-modulated radiotherapy, non-IGRT non-image-guided radiotherapy, OTTRT overall treatment time of radiotherapy, POTT package of overall treatment time
